Literature DB >> 26138088

The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.

P Sale1, D Castiglioni, M F De Pandis, M Torti, V Dall'armi, F G Radicati, F Stocchi.   

Abstract

BACKGROUND: The Lee Silverman Voice Treatment (LSVT®) was specifically created and tested to comply with the needs of individuals with Parkinson's disease (PD) and other neurological problems. This is a high effort intensive treatment that aims at increasing vocal intensity through the increase of subglottal air pressure, i.e. respiratory effort, for a better cordal adduction and vibration, following the motto "think loud". AIM: The main goal of this study is to inspect the efficacy of LSVT® treatment in progressive supranuclear palsy (PSP) patients.
DESIGN: Longitudinal study.
SETTING: Rehabilitative inpatient unit. POPULATION: Sixteen patients with PSP and 23 patients with idiopathic PD as control were enrolled in the study.
METHODS: All patients underwent a training consisting in16 sessions of speech therapy following the LSVT® protocol. Initially the two groups of patients had similar voice problems, i.e. low volume and bad articulation of speech.
RESULTS: A statistically significant improvement was found among the data collected before and after treatment in the PSP and Parkinson groups. Increase in maximum phonation duration and volume of voice in reading were similar in the two groups. Improvement in quality of voice and articulation were more significant in the PD group as compared to the PSP group.
CONCLUSION: These results, along with previous findings, add further support to the generalized therapeutic impact of intensive voice treatment on respiratory and laryngeal functions in individuals with PSP. CLINICAL REHABILITATION IMPACT: The positive results, the absence of dropout and collateral effect following this clinical treatments with LSVT technique encouraged to use this technique in PSP patients.

Entities:  

Mesh:

Year:  2015        PMID: 26138088

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  7 in total

1.  Language boosting by transcranial stimulation in progressive supranuclear palsy.

Authors:  Antoni Valero-Cabré; Clara Sanches; Juliette Godard; Oriane Fracchia; Bruno Dubois; Richard Levy; Dennis Q Truong; Marom Bikson; Marc Teichmann
Journal:  Neurology       Date:  2019-07-03       Impact factor: 9.910

Review 2.  Progressive Supranuclear Palsy: an Update.

Authors:  Melissa J Armstrong
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-17       Impact factor: 5.081

Review 3.  Managing cognition in progressive supranuclear palsy.

Authors:  Timothy Rittman; Ian Ts Coyle-Gilchrist; James B Rowe
Journal:  Neurodegener Dis Manag       Date:  2016-11-23

4.  Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).

Authors:  Lorraine Ramig; Angela Halpern; Jennifer Spielman; Cynthia Fox; Katherine Freeman
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

5.  Effects of Lee Silverman Voice Treatment (LSVT LOUD) on Swallowing in Patients with Progressive Supranuclear Palsy: A Pilot Study.

Authors:  Sonoko Nozaki; Masako Fujiu-Kurachi; Takako Tanimura; Kimiyo Ishizuka; Eri Miyata; Shuhei Sugishita; Takahisa Imai; Maiko Nishiguchi; Mitsuru Furuta; Shiro Yorifuji
Journal:  Prog Rehabil Med       Date:  2021-02-20

6.  Voice Analysis for Neurological Disorder Recognition-A Systematic Review and Perspective on Emerging Trends.

Authors:  Pascal Hecker; Nico Steckhan; Florian Eyben; Björn W Schuller; Bert Arnrich
Journal:  Front Digit Health       Date:  2022-07-07

Review 7.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.